# CheckMate 451 (NCT02538666)

> An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02538666
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Lung Cancer
- Interventions: Nivolumab; Ipilimumab; Placebo
- Enrollment: 907
- Primary outcome: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 4
- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-451-nct02538666

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02538666", "email": "<work email>"}; the inbox owner confirms by the emailed link.